Is there a rationale for insulin therapy in pre-diabetic individuals?

Area of Science:

• Endocrinology
• Metabolic Diseases
• Cardiovascular Medicine

Background:

• Type 2 diabetes mellitus (T2DM) is often preceded by impaired glucose tolerance (IGT) and impaired fasting glucose (IFG), collectively known as pre-diabetes.
• Pre-diabetes is characterized by beta-cell dysfunction and insulin resistance, increasing the risk of both diabetes and cardiovascular disease (CVD).
• Micro- and macrovascular complications associated with T2DM contribute to significant morbidity and mortality, with risks extending to individuals with pre-diabetes.

Purpose of the Study:

• To investigate the potential of exogenous insulin treatment, specifically insulin glargine, to reduce cardiovascular risk in individuals with T2DM or pre-diabetes.
• To explore whether insulin glargine can overcome barriers associated with insulin initiation, such as hypoglycemia and weight gain.
• To evaluate the efficacy of insulin glargine in improving glycemic control and potentially preventing the progression to T2DM and associated cardiovascular events.

Main Methods:

• Initial studies explored low-dose insulin glargine combined with caloric restriction to achieve near-normoglycemia in pre-diabetes.
• The ongoing ORIGIN (Outcomes Reduction with Initial Glargine INtervention) study is evaluating insulin glargine's impact on cardiovascular morbidity and mortality.
• The ORIGIN study compares near-normoglycemia treatment with insulin glargine against conventional management in individuals with IGT, IFG, or new-onset T2DM.

Main Results:

• Preliminary findings suggest that low-dose insulin glargine plus caloric restriction is a feasible approach for treating pre-diabetes.
• Insulin glargine demonstrated a flat time-action profile, near 24-hour duration, reduced hypoglycemia risk, and improved glycemic control compared to NPH insulin.
• The ORIGIN study aims to determine if insulin glargine treatment reduces cardiovascular events and the progression rate to T2DM.

Conclusions:

• Insulin glargine shows promise in managing pre-diabetes and potentially mitigating cardiovascular risks associated with dysglycemia.
• Further research is warranted to fully elucidate the benefits of insulin therapy in individuals with pre-diabetes.
• Early intervention with insulin glargine may offer a strategy to reduce cardiovascular morbidity and mortality in at-risk populations.